Literature DB >> 2124648

Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in post-menopausal women.

A R Aedo1, B M Landgren, E Diczfalusy.   

Abstract

The pharmacokinetic properties and biotransformation of two orally active oestrogens, piperazine oestrone sulphate (PE1S, 2.5 mg/day) and oestradiol valerate (E2V, 2.0 mg/day), given alone or in combination with levonorgestrel (LNG, 250 micrograms/day) were compared in 8 post-menopausal women, using a randomized cross-over design. The end points measured in peripheral plasma included oestrone (E1), oestradiol (E2), oestriol (E3), oestrone sulphate (E1S), oestradiol sulphate (E2S) and oestriol sulphate (E3S). In addition, LNG and sex-hormone-binding globulin SHBG concentrations were also assessed. The plasma levels of E3 were invariably below the detection limit (220 pmol/l). The levels of all the other oestrogens analyzed were consistently higher and the area under the curve significantly greater (except in the case of E3S) following PE1S administration than those recorded after E2V ingestion. The terminal half-lives of the circulating oestrogens measured after PE1S administration did not differ from those found after E2V administration. After 21 days of PE1S administration (in combination with LNG for the last 10 days), the maximum levels of all the oestrogens (except those of E2) were significantly higher than those seen after the first dose. No such difference was observed after E2V administration. There was no difference between the effects of the two treatment regimens with regard to the E1/E2 ratios, but the E1/E1S ratios were significantly lower after PE1S treatment than after E2V administration. It is concluded that, compared with an equivalent dose of PE1S, daily repeated oral administration of E2V yields consistently lower peripheral plasma levels of E2 and its principal metabolites. However, in contrast to PE1S therapy, prolonged administration of E2V does not result in an accumulation of the circulating oestrogens measured.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2124648     DOI: 10.1016/0378-5122(90)90013-v

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  4 in total

1.  A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.

Authors:  Marta Valle; Enrico Di Salle; Maria Gabriella Jannuzzo; Italo Poggesi; Maurizio Rocchetti; Riccardo Spinelli; Davide Verotta
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

2.  Differential effects of hormone therapy on serotonin, vascular function and mood in the KEEPS.

Authors:  L Raz; L V Hunter; N M Dowling; W Wharton; C E Gleason; M Jayachandran; L Anderson; S Asthana; V M Miller
Journal:  Climacteric       Date:  2015-12-10       Impact factor: 3.005

3.  The effect of ketoconazole and diltiazem on oestrogen metabolism in postmenopausal women after single dose oestradiol treatment.

Authors:  Anita Annas; Kjell Carlström; Gunnar Alván; Ayman AL-Shurbaji
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

Review 4.  Improving clinical outcomes through attention to sex and hormones in research.

Authors:  Michelle M Mielke; Virginia M Miller
Journal:  Nat Rev Endocrinol       Date:  2021-07-27       Impact factor: 47.564

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.